Asset

Clemidsogene Lanparvovec

REGENXBIO Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (2)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT03566043phase2_3active_not_recruiting2018-09-272023-11-27REGENXBIO Inc.CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)
NCT04571970phase1_2completed2021-03-112023-05-09REGENXBIO Inc.RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)